☆ 4.7 Article

Prospective Phase II Trial of Prognostication by 68Ga-NOTA-AE105 uPAR PET in Patients with Neuroendocrine Neoplasms: Implications for uPAR-Targeted Therapy

JOURNAL OF NUCLEAR MEDICINE (2022)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Article Radiology, Nuclear Medicine & Medical Imaging

Urokinase-Type Plasminogen Activator Receptor (uPAR) PET/MRI of Prostate Cancer for Noninvasive Evaluation of Aggressiveness: Comparison with Gleason Score in a Prospective Phase 2 Clinical Trial

Marie Obro Fosbol et al.

Summary: The study aimed to evaluate the correlation between uptake of the PET ligand Ga-68-NOTA-AE105 and Gleason score in patients undergoing prostate biopsy. Results showed a significant positive correlation between SUVmax and Gleason score. SUVmax could discriminate between low-risk Gleason score profiles and intermediate risk Gleason score profiles accurately.

JOURNAL OF NUCLEAR MEDICINE (2021)

添加到收藏夹

Article Radiology, Nuclear Medicine & Medical Imaging

18F-FDG PET is Superior to WHO Grading as a Prognostic Tool in Neuroendocrine Neoplasms and Useful in Guiding PRRT: A Prospective 10-Year Follow-up Study

Tina Binderup et al.

Summary: This study demonstrated the long-term prognostic value of F-18-FDG PET imaging for risk stratification of neuroendocrine neoplasms, surpassing tumor grading. F-18-FDG PET is able to differentiate low- and high-risk groups even within G1 and G2 tumors, providing valuable information for treatment selection and risk assessment in NEN patients.

JOURNAL OF NUCLEAR MEDICINE (2021)

添加到收藏夹

Article Radiology, Nuclear Medicine & Medical Imaging

Semiautomatic Tumor Delineation for Evaluation of 64Cu-DOTATATE PET/CT in Patients with Neuroendocrine Neoplasms: Prognostication Based on Lowest Lesion Uptake and Total Tumor Volume

Esben Andreas Carlsen et al.

Summary: This study associated Cu-64-DOTATATE PET/CT imaging results with survival outcomes in patients with neuroendocrine neoplasms, finding significant associations of minimum SUVmean and total tumor volume with PFS and OS. A novel prognostic classification system based on lesion uptake and total tumor volume was proposed for NENs patients.

JOURNAL OF NUCLEAR MEDICINE (2021)

添加到收藏夹

Article Oncology

Nordic guidelines 2021 for diagnosis and treatment of gastroenteropancreatic neuroendocrine neoplasms

Eva Tiensuu Janson et al.

Summary: These Nordic guidelines summarize the current view of the Nordic Neuroendocrine Tumour Group on how to diagnose and treat GEP-NEN patients, aiming to be useful for clinicians in their daily practice.

ACTA ONCOLOGICA (2021)

添加到收藏夹

Review Biochemistry & Molecular Biology

The Urokinase Receptor: A Multifunctional Receptor in Cancer Cell Biology. Therapeutic Implications

Anna Li Santi et al.

Summary: Proteolysis is crucial in biological processes, but must be tightly controlled to prevent adverse effects. The plasminogen activation (PA) system plays a key role in cancer, with uPAR involved in cancer cell biology.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)

添加到收藏夹

Review Biochemistry & Molecular Biology

Fibrinolytic System and Cancer: Diagnostic and Therapeutic Applications

Niaz Mahmood et al.

Summary: Fibrinolysis plays a crucial role in maintaining hemostatic balance and is directly linked to tumor growth, invasiveness, and metastasis. Despite promising preclinical evidence on targeting key components of the fibrinolytic system for cancer therapy, limited clinical trials have prevented successful translation from bench to bedside.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)

添加到收藏夹

Review Oncology

PRRT in high-grade gastroenteropancreatic neuroendocrine neoplasms (WHO G3)

Halfdan Sorbye et al.

ENDOCRINE-RELATED CANCER (2020)

添加到收藏夹

Article Radiology, Nuclear Medicine & Medical Imaging

64Cu-DOTATATE PET/CT and Prediction of Overall and Progression-Free Survival in Patients with Neuroendocrine Neoplasms

Esben Andreas Carlsen et al.

JOURNAL OF NUCLEAR MEDICINE (2020)

添加到收藏夹

Article Medicine, General & Internal

Soluble Urokinase Plasminogen Activator Receptor (suPAR) Concentrations Are Elevated in Patients with Neuroendocrine Malignancies

Burcin Oezdirik et al.

JOURNAL OF CLINICAL MEDICINE (2020)

添加到收藏夹

Article Cell & Tissue Engineering

uPAR antibody (huATN-658) and Zometa reduce breast cancer growth and skeletal lesions

Niaz Mahmood et al.

BONE RESEARCH (2020)

添加到收藏夹

Article Biochemical Research Methods

Proteomics Reveals Cell-Surface Urokinase Plasminogen Activator Receptor Expression Impacts Most Hallmarks of Cancer

Seong Beom Ahn et al.

PROTEOMICS (2019)

添加到收藏夹

Review Oncology

Multifaceted Role of the Urokinase-Type Plasminogen Activator (uPA) and its Receptor (uPAR): Diagnostic, Prognostic, and Therapeutic Applications

Niaz Mahmood et al.

FRONTIERS IN ONCOLOGY (2018)

添加到收藏夹

Article Radiology, Nuclear Medicine & Medical Imaging

Safety, Dosimetry, and Tumor Detection Ability of 68Ga-NOTA-AE105: First-in-Human Study of a Novel Radioligand for uPAR PET Imaging

Dorthe Skovgaard et al.

JOURNAL OF NUCLEAR MEDICINE (2017)

添加到收藏夹

Article Endocrinology & Metabolism

ENETS Consensus Recommendations for the Standards of Care in Neuroendocrine Neoplasms: Follow-Up and Documentation

U. Knigge et al.

NEUROENDOCRINOLOGY (2017)

添加到收藏夹

Article Medicine, General & Internal

Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors

J. Strosberg et al.

NEW ENGLAND JOURNAL OF MEDICINE (2017)

添加到收藏夹

Article Radiology, Nuclear Medicine & Medical Imaging

Prognostic Value of 18F-FLT PET in Patients with Neuroendocrine Neoplasms: A Prospective Head-to-Head Comparison with 18F-FDG PET and Ki-67 in 100 Patients

Camilla B. Johnbeck et al.

JOURNAL OF NUCLEAR MEDICINE (2016)

添加到收藏夹

Article Medicine, Research & Experimental

uPAR Targeted Radionuclide Therapy with 177Lu-DOTA-AE105 Inhibits Dissemination of Metastatic Prostate Cancer

Morten Persson et al.

MOLECULAR PHARMACEUTICS (2014)

添加到收藏夹

Article Oncology

Phase II randomised proof-of-concept study of the urokinase inhibitor upamostat (WX-671) in combination with gemcitabine compared with gemcitabine alone in patients with non-resectable, locally advanced pancreatic cancer

V. Heinemann et al.

BRITISH JOURNAL OF CANCER (2013)

添加到收藏夹

Article Radiology, Nuclear Medicine & Medical Imaging

New peptide receptor radionuclide therapy of invasive cancer cells: in vivo studies using 177Lu-DOTA-AE105 targeting uPAR in human colorectal cancer xenografts

Morten Persson et al.

NUCLEAR MEDICINE AND BIOLOGY (2012)

添加到收藏夹

Article Radiology, Nuclear Medicine & Medical Imaging

68Ga-labeling and in vivo evaluation of a uPAR binding DOTA- and NODAGA-conjugated peptide for PET imaging of invasive cancers

Morten Persson et al.

NUCLEAR MEDICINE AND BIOLOGY (2012)

添加到收藏夹

Article Multidisciplinary Sciences

Cutoff Finder: A Comprehensive and Straightforward Web Application Enabling Rapid Biomarker Cutoff Optimization

Jan Budczies et al.

PLOS ONE (2012)

添加到收藏夹

Review Biochemistry & Molecular Biology

Hallmarks of Cancer: The Next Generation

Douglas Hanahan et al.

CELL (2011)

添加到收藏夹

Article Pharmacology & Pharmacy

Rational Targeting of the Urokinase Receptor (uPAR): Development of Antagonists and Non-Invasive Imaging Probes

M. C. Kriegbaum et al.

CURRENT DRUG TARGETS (2011)

添加到收藏夹

Article Oncology

18F-Fluorodeoxyglucose Positron Emission Tomography Predicts Survival of Patients with Neuroendocrine Tumors

Tina Binderup et al.

CLINICAL CANCER RESEARCH (2010)

添加到收藏夹

Article Oncology

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

E. A. Eisenhauer et al.

EUROPEAN JOURNAL OF CANCER (2009)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.